However, the confocal microscopic evaluation of colonic samples prior to the initiation of Infliximab therapy as well as following therapy showed that IBD patients had a substantial decrease or complete loss of ANXA1 protein expression in the colonic mucosa. Here, ANXA1 is linked to inflammatory bowel disease.